Skip to main content
  • Advertise
    Want to Advertise with Us?
    Conquer welcomes advertising and sponsorship collaborations with reputable companies offering high-quality products and services to people affected by cancer.
  • Affiliated Brands
    Academy of Oncology Nurse & Patient Navigators
    The Academy of Oncology Nurse & Patient Navigators (AONN+) is the largest national specialty organization dedicated to improving patient care and quality of life by defining, enhancing, and promoting the role of oncology nurse and patient navigators. Our organization of over 8,900 members was founded in May 2009 to provide a network for all professionals involved and interested in patient navigation and survivorship care services to better manage the complexities of the cancer care treatment continuum for their patients. We view our organization as one consisting of “professional patient advocates” and, to that end, we support and serve our members.
    Journal of Oncology Navigation & Survivorship
    The Journal of Oncology Navigation & Survivorship (JONS) promotes reliance on evidence-based practices in navigating patients with cancer and their caregivers through diagnosis, treatment, and survivorship. JONS also seeks to strengthen the role of nurse and patient navigators in cancer care by serving as a platform for these professionals to disseminate original research findings, exchange best practices, and find support for their growing community.
    The Oncology Nurse-APN/PA
    The Oncology Nurse-APN/PA (TON) provides coverage of the wide spectrum of oncology-related events, trends, news, therapeutics, diagnostics, organizations, and legislation that directly affect hematology/oncology nurses and advanced practitioners involved in healthcare delivery and product utilization. The scope and coverage include a unique presentation of news and events that are shaping the care of patients with cancer.
  • Healthcare Providers
  • Contribute

Nubeqa Approved for Men with Metastatic Hormone-Sensitive Prostate Cancer

October 2022 Vol 8 No 5

On August 5, 2022, the FDA approved Nubeqa (darolutamide; from Bayer Healthcare), an androgen receptor inhibitor, for use with chemotherapy (docetaxel), for the treatment of men with metastatic (spreading) hormone-sensitive prostate cancer. Nubeqa was previously approved for men with nonmetastatic castration-resistant prostate cancer.

Matthew Smith, MD, PhD
Matthew Smith, MD, PhD

“Nubeqa plus ADT [androgen-deprivation therapy] and docetaxel has shown significant benefit in overall survival and a favorable safety profile for patients with metastatic hormone-sensitive prostate cancer,” said Matthew Smith, MD, PhD, Massachusetts General Hospital Cancer Center.

The approval of this new indication was based on results of the randomized, multicenter, double-blind, placebo-controlled phase 3 clinical trial that included 1306 men with metastatic hormone-sensitive prostate cancer.

Many of the patients who received Nubeqa in the study have continued to respond to the treatment after the study was over. By contrast, the average time of survival was about 4 years (48.9 months) in men who received placebo plus chemotherapy, meaning that their tumor stopped responding to the treatment.

The most common side effects reported in 10% or more of the men were constipation, decreased appetite, rash, bleeding, weight gain, and elevated blood pressure. Abnormal blood tests were reported for more than 30% of the patients.

Recommended For You